Tag Archives: System Complexity and Informational Complaints: Medtech Opportunity Costs Deter Adopters (Barriers to Innovation)

Innovation in the NHS: Accelerated Access Review Interim Report (NHS England / Department of Health / AAR)

Posted on October 29, 2015 by Dementia and Elderly Care News

Summary The Accelerated Access Review: Interim Report (AAR) explores innovation within the NHS in terms of accelerated access of drugs, devices, diagnostics and digital health products. There are said to be five emerging themes: Proposition One: Putting the patient centre … Continue reading →

Posted in Acute Hospitals, Commissioning, Community Care, Department of Health, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, Management of Condition, National, NHS, NHS England, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged 5YFV: NHS Five Year Forward View, Accelerated Access Review, Accelerated Access Review Interim Report, Access to Transformative Health Technology, Affordability (Facilitators of Innovation), Barriers in Access to Transformative Health Technology (AAR): Capacity and Capability, Barriers in Access to Transformative Health Technology (AAR): Culture, Barriers in Access to Transformative Health Technology (AAR): Data and Evidence, Barriers in Access to Transformative Health Technology (AAR): Dominance of Pharma Paradigm, Barriers in Access to Transformative Health Technology (AAR): Finance and Budgeting, Barriers in Access to Transformative Health Technology (AAR): Immaturity and Uncertainty of the Landscape, Barriers in Access to Transformative Health Technology (AAR): System Complexity and Informational Complaints, Barriers to Accessing Transformative Health Technology, Barriers to Engagement, Barriers to Innovation, Barriers to Integration, Building on Existing Regulatory Flexibilities for Innovation (Facilitators of Innovation), Capacity and Capability: Business Cases Time Consuming /Challenging (Barriers to Innovation), Capacity and Capability: Constraints on System Capacity to Adopt (Barriers to Innovation), Capacity and Capability: Decommissioning to ‘Free Up’ Capacity Rare (Barriers to Innovation), Capacity and Capability: Horizon Scanning Poorly Utilised (Barriers to Innovation), Capacity and Capability: Insufficient Skills to Adopt Innovation (Barriers to Innovation), Capacity and Capability: Insufficient Small and Medium-Sized Enterprises (SME) Resource (Barriers to Innovation), Capacity and Capability: Lack of Planning (Barriers to Innovation), Capacity and Capability: Lack of Resources to Train / Support Adoption (Barriers to Innovation), Commissioning for Transformation, Culture: Disconnect Between Clinical Need and Product Development (Barriers to Innovation), Culture: Industry Unwilling to Pilot New Approaches (Barriers to Innovation), Culture: Lack of Accountability for Innovation (Barriers to Innovation), Culture: Lack of Leadership Support for Innovation (Barriers to Innovation), Culture: Misalignment of Key Stakeholder Objectives (Barriers to Innovation), Culture: Patient Resistance/Fear of Adverse Outcomes (Barriers to Innovation), Culture: Players Unwilling to Make Concessions (Barriers to Innovation), Culture: Provider/Commissioner Risk Aversion (Barriers to Innovation), Culture: Silo Thinking in System (Barriers to Innovation), Data / Evidence on Safety / Efficacy / Value (Facilitators of Innovation), Data and Evidence: Access to NHS Data Limited (Barriers to Innovation), Data and Evidence: Data Systems Not In Place Across Pathway (Barriers to Innovation), Data and Evidence: Evidence Needed for Uptake Varies Locally (Barriers to Innovation), Data and Evidence: Evidence Needs Not Considered in Early Development (Barriers to Innovation), Data and Evidence: Failure to Generate Data for Reimbursement (Barriers to Innovation), Data and Evidence: Insufficient Safety Data (Barriers to Innovation), Data and Evidence: Lack of Outcomes Data to Drive Uptake (Barriers to Innovation), Data and Evidence: Mismatched Evidence for Licensing and Reimbursement (Barriers to Innovation), Department for Business Innovation and Skills (BIS), Development and Regulatory Pathways Redesigned for Innovation (Facilitators of Innovation), Dominance of Pharma Paradigm: Challenging Approval of Companion Diagnostics (Barriers to Innovation), Dominance of Pharma Paradigm: Horizon Scanning Limited Beyond Pharma (Barriers to Innovation), Dominance of Pharma Paradigm: No Clear Digital Pathway (Barriers to Innovation), Dominance of Pharma Paradigm: Questions Around NICE Value Without Funding Direction (Barriers to Innovation), Dominance of Pharma Paradigm: The National Institute for Health and CARE Excellence (NICE) Processes Based on Pharma (Barriers to Innovation), Dr Harpreet Sood: Senior Fellow to the Chair and Chief Executive’s Office of NHS England, Dr Stephen Brecker (Consultant Cardiologist), Finance and Budgeting: Affordability (Barriers to Innovation), Finance and Budgeting: Budget Siloes - Across Organisations or Sectors (Barriers to Innovation), Finance and Budgeting: Budget Siloes - Across Years (Barriers to Innovation), Finance and Budgeting: Decommissioning Rare (Barriers to Innovation), Finance and Budgeting: Insufficient Financial Support for Adoption (Barriers to Innovation), Finance and Budgeting: No Funding Direction for Medtech /Diagnostics (Barriers to Innovation), Finance and Budgeting: No Pricing Framework (Barriers to Innovation), Finance and Budgeting: Pricing / Contracting Update (Tariffs) Slow (Barriers to Innovation), From Theory to Theatre, George Freeman MP: Former Life Sciences Minister, Giving Innovators More Clarity on Data Requirements Throughout Pathway (Facilitators of Innovation), Harpreet Sood, Health Action Plan, Immaturity and Uncertainty of Landscape: Access / Innovation Initiatives From NHSE and Academic Health Science Networks (AHSNs) At An Early Stage (Barriers to Innovation), Immaturity and Uncertainty of Landscape: Benefits of Early Access to Medicines Scheme (EAMS) Not Persuasive (Barriers to Innovation), Immaturity and Uncertainty of Landscape: Gap Between Early Access to Medicines Scheme (EAMS) or Industry Funding in Routine Commissioning (Barriers to Innovation), Incentives for Use of Transformative Health Technology (Facilitators of Innovation), Increased Patient and Public Involvement (Facilitators of Innovation), Increased Patient and Public Involvement in Funding Decisions (Facilitators of Innovation), Increased Patient and Public Involvement in Regulatory Processes (Facilitators of Innovation), Innovation in the NHS, Integrated Clinician Entrepreneur Training Scheme, Integration of Health and Care, Investing for Transformation, Learning Disability Skills and Competency Framework, Local Transformation Plans for Children and Young People’s Health and Wellbeing, Long-Term Strategies for Reimbursing New Technologies (Facilitators of Innovation), MHP Health, More Flexible Funding Systems (Facilitators of Innovation), New Models of Care, NHS England's Five Year Forward View (2014), NHS Five Year Forward View (5YFV), NHS Integrated Clinician Entrepreneur Training Scheme, NHS Test Bed Programme, NICE Service Model Guidance: Learning Disabilities and Challenging Behaviour, Patient and Public Involvement, Patient and Public Involvement (Facilitators of Innovation), Personalised Care and Support Planning (PCSP), Positive and Proactive Care, Professor Sir John Bell: Chair of Accelerated Access Review’s Expert Advisory Group, Removal of Barriers to Transformative Health Technology (Facilitators of Innovation), Royal College of Surgeons of England (RCSENG), Support for Uptake of Transformative Health Technology (Facilitators of Innovation), Surgical Innovation, System Complexity and Informational Complaints: Confusion About Regulatory Needs of Devices and Digital (Barriers to Innovation), System Complexity and Informational Complaints: Lack of Clarity Around NHS / Patient Needs (Barriers to Innovation), System Complexity and Informational Complaints: Lack of Clarity on Existing Regulatory Flexibilities (Barriers to Innovation), System Complexity and Informational Complaints: Lack of Early Dialogue/Advice From Regulators (Barriers to Innovation), System Complexity and Informational Complaints: Lack of Support for Complex Process Change (Barriers to Innovation), System Complexity and Informational Complaints: Medtech Opportunity Costs Deter Adopters (Barriers to Innovation), System Complexity and Informational Complaints: No Coherent Procurement Framework (Barriers to Innovation), System Complexity and Informational Complaints: No Register of Regulated Products (Barriers to Innovation), System Complexity and Informational Complaints: Overly Complex Commissioning Process/Duplication (Barriers to Innovation), System Complexity and Informational Complaints: SMEs Lack Experience Selling to NHS (Barriers to Innovation) | Leave a comment